These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38062606)

  • 1. Commodifying Vaccines to Curtail Antibiotic Resistance Impact in Malaria Endemic Countries.
    Khan M
    J Coll Physicians Surg Pak; 2023 Dec; 33(12):1454-1456. PubMed ID: 38062606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malaria vaccines to moderate the impact of antibiotic resistance in endemic countries.
    Khan M; Khan S
    J Med Microbiol; 2023 Jul; 72(7):. PubMed ID: 37493512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.
    Penny MA; Verity R; Bever CA; Sauboin C; Galactionova K; Flasche S; White MT; Wenger EA; Van de Velde N; Pemberton-Ross P; Griffin JT; Smith TA; Eckhoff PA; Muhib F; Jit M; Ghani AC
    Lancet; 2016 Jan; 387(10016):367-375. PubMed ID: 26549466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models.
    Penny MA; Galactionova K; Tarantino M; Tanner M; Smith TA
    BMC Med; 2015 Jul; 13():170. PubMed ID: 26219380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].
    Vandoolaeghe P; Schuerman L
    Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
    Owusu-Agyei S; Ansong D; Asante K; Kwarteng Owusu S; Owusu R; Wireko Brobby NA; Dosoo D; Osei Akoto A; Osei-Kwakye K; Adjei EA; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Vekemans J; Ofori-Anyinam O; Leach A; Lievens M; Demoitie MA; Dubois MC; Cohen J; Ballou WR; Savarese B; Chandramohan D; Gyapong JO; Milligan P; Antwi S; Agbenyega T; Greenwood B; Evans J
    PLoS One; 2009 Oct; 4(10):e7302. PubMed ID: 19806184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Advanced Development Pathway of the RTS,S/AS01 Vaccine.
    von Seidlein L
    Methods Mol Biol; 2019; 2013():177-187. PubMed ID: 31267502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malaria vaccine: a bright prospect for elimination of malaria.
    Bairwa M; Rajput M; Khanna P; Rohilla R; Verma R; Chawla S
    Hum Vaccin Immunother; 2012 Jun; 8(6):819-22. PubMed ID: 22739688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.
    Vandoolaeghe P; Schuerman L
    Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling population-level impact to inform target product profiles for childhood malaria vaccines.
    Hogan AB; Winskill P; Verity R; Griffin JT; Ghani AC
    BMC Med; 2018 Jul; 16(1):109. PubMed ID: 30001708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report.
    Merle CS;
    Malar J; 2023 Aug; 22(1):242. PubMed ID: 37612716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
    Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
    Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission.
    Brooks A; Briët OJ; Hardy D; Steketee R; Smith TA
    PLoS One; 2012; 7(3):e32587. PubMed ID: 22412892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
    Galactionova K; Tediosi F; Camponovo F; Smith TA; Gething PW; Penny MA
    Vaccine; 2017 Jan; 35(1):53-60. PubMed ID: 27890400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
    Agnandji ST; Fernandes JF; Bache EB; Ramharter M
    Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan.
    Mahmoudi S; Keshavarz H
    Hum Vaccin Immunother; 2017 Sep; 13(9):2098-2101. PubMed ID: 28272979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program.
    Baral R; Levin A; Odero C; Pecenka C; Tanko Bawa J; Antwi-Agyei KO; Amponsa-Achaino K; Chisema MN; Eddah Jalango R; Mkisi R; Gordon S; Morgan W; Muhib F
    Vaccine; 2023 Feb; 41(8):1496-1502. PubMed ID: 36710234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.
    Olotu A; Moris P; Mwacharo J; Vekemans J; Kimani D; Janssens M; Kai O; Jongert E; Lievens M; Leach A; Villafana T; Savarese B; Marsh K; Cohen J; Bejon P
    PLoS One; 2011; 6(10):e25786. PubMed ID: 21998698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malaria Vaccines: Progress to Date.
    Stanisic DI; Good MF
    BioDrugs; 2023 Nov; 37(6):737-756. PubMed ID: 37728713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi.
    Bell GJ; Loop M; Topazian HM; Hudgens M; Mvalo T; Juliano JJ; Kamthunzi P; Tegha G; Mofolo I; Hoffman I; Bailey JA; Emch M
    Vaccine; 2020 May; 38(25):4079-4087. PubMed ID: 32362527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.